Surmodics, Inc. (NASDAQ:SRDX) Shares Acquired by Wolverine Asset Management LLC

Wolverine Asset Management LLC increased its holdings in Surmodics, Inc. (NASDAQ:SRDX) by 6.9% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 27,766 shares of the company’s stock after acquiring an additional 1,800 shares during the quarter. Wolverine Asset Management LLC owned approximately 0.19% of Surmodics worth $1,077,000 at the end of the most recent quarter.

Several other institutional investors also recently bought and sold shares of the company. SG Americas Securities LLC boosted its position in shares of Surmodics by 14.7% in the 1st quarter. SG Americas Securities LLC now owns 5,138 shares of the company’s stock worth $151,000 after buying an additional 660 shares in the last quarter. Lazard Asset Management LLC boosted its holdings in Surmodics by 13.4% in the 1st quarter. Lazard Asset Management LLC now owns 5,679 shares of the company’s stock worth $166,000 after acquiring an additional 673 shares during the period. BNP Paribas Financial Markets boosted its stake in shares of Surmodics by 7.5% during the 1st quarter. BNP Paribas Financial Markets now owns 6,878 shares of the company’s stock valued at $202,000 after buying an additional 481 shares during the last quarter. Hardin Capital Partners LLC bought a new position in Surmodics during the second quarter worth $206,000. Finally, The Manufacturers Life Insurance Company bought a new position in Surmodics during the second quarter worth $229,000. 96.63% of the stock is owned by institutional investors and hedge funds.

Surmodics Trading Up 0.2 %

Shares of SRDX stock opened at $38.56 on Wednesday. Surmodics, Inc. has a 12-month low of $25.17 and a 12-month high of $42.44. The company has a market capitalization of $550.14 million, a P/E ratio of -47.60 and a beta of 1.20. The firm has a 50-day moving average price of $38.54 and a 200 day moving average price of $39.04. The company has a quick ratio of 3.22, a current ratio of 3.98 and a debt-to-equity ratio of 0.25.

Surmodics (NASDAQ:SRDX) last announced its quarterly earnings results on Wednesday, November 6th. The company reported ($0.13) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.27) by $0.14. The firm had revenue of $33.23 million during the quarter, compared to the consensus estimate of $30.69 million. Surmodics had a negative net margin of 9.15% and a negative return on equity of 3.77%. Research analysts forecast that Surmodics, Inc. will post 0.17 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of research analysts have recently commented on SRDX shares. Needham & Company LLC reissued a “hold” rating on shares of Surmodics in a report on Thursday, November 7th. StockNews.com started coverage on Surmodics in a report on Thursday, November 7th. They issued a “hold” rating for the company. Five equities research analysts have rated the stock with a hold rating, According to MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $50.00.

About Surmodics

Surmodics, Inc, together with its subsidiaries, provides performance coating technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates through two segments, Medical Device and In Vitro Diagnostics (IVD).